The state of Arizona currently has 4 active clinical trials seeking participants for Primary Biliary Cholangitis research studies. These trials are conducted in various cities, including Phoenix, Tucson, Scottsdale and Mesa.
A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis
Recruiting
The participants of this study will have confirmed Primary Biliary Cholangitis (PBC). Participants will also have inadequate response or intolerance to ursodeoxycholic acid (UDCA) a drug used to treat PBC. PBC is a disease that progresses slowly. It causes damage to the bile ducts in the liver, leading to a build-up of bile acids which causes further damage. The liver damage in PBC may lead to scarring (cirrhosis). PBC may also be associated with multiple symptoms. Many people with PBC may re... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/27/2024
Locations: Arizona Liver Health, Tucson, Arizona
Conditions: Primary Biliary Cholangitis (PBC)
IDEAL: Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA)
Recruiting
To Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects with Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA)
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
03/19/2024
Locations: The Institute for Liver Health II dba Arizona Liver Health, Chandler, Arizona
Conditions: Primary Biliary Cholangitis
An Open-Label Study Following Oral Dosing of Seladelpar to Subjects With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)
Recruiting
The Effect of Hepatic Impairment on The Pharmacokinetics of Seladelpar: An Open-Label Study Following Oral Dosing of Seladelpar to Subjects with Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
01/26/2024
Locations: The Institute of Liver Health dba Arizona Liver Health, Chandler, Arizona
Conditions: Primary Biliary Cholangitis, Compensated Cirrhosis, Hepatic Impairment
Saroglitazar Magnesium for Treatment of Primary Biliary Cholangitis
Recruiting
Saroglitazar Magnesium 1 mg and 2 mg tablets for treatment of subjects with Primary Biliary Cholangitis (PBC)
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
12/30/2023
Locations: Zydus US021, Tucson, Arizona
Conditions: Primary Biliary Cholangitis